Results 61 to 70 of about 3,046 (215)

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value [PDF]

Journal of Managed Care & Specialty Pharmacy, 2022
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions.
Molly, Beinfeld, Jason H, Wasfy, Surrey, Walton, Jyotirmoy, Sarker, Emily, Nhan, David M, Rind, Steven D, Pearson   +6 more
openaire   +2 more sources

Mavacamten - the first disease-specific pharmacological treatment of hypertrophic cardiomyopathy Mavacamten – ny behandling av hypertrofisk kardiomyopati

, 2021
Mavacamten, a selective inhibitor of cardiac myosin ATPase, which reduces hypercontractility, is the first disease-specific treatement of HCM. In phase 2 trials including persons with HCM without outflow obstruction, a significant reduction in NT-proBNP ...
Magnusson, P., Karason, Kristjan,
core  

[Mavacamten - the first disease-specific pharmacological treatment of hypertrophic cardiomyopathy]

, 2021
Mavacamten, a selective inhibitor of cardiac myosin ATPase, which reduces hypercontractility, is the first disease-specific treatement of HCM. In phase 2 trials including persons with HCM without outflow obstruction, a significant reduction in NT-proBNP ...
Karason, K, Magnusson, P,
core  

Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease
Background Cardiac myosin inhibitors were recently developed to address the underlying pathophysiology of hypertrophic cardiomyopathy and to improve symptoms and quality of life.
Bryton Davis, Hailey Volk, O. Nguyen, D. Kamna, Hongya Chen, R. Barriales-Villa, P. García-Pavía, I. Olivotto, A. Owens, C. Coats, T. Abraham, S. Solomon, M. Maron, A. Masri   +13 more
semanticscholar   +1 more source

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet, 2020
BACKGROUND Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction.
I. Olivotto, A. Oręziak, R. Barriales-Villa, Theodore P. Abraham, A. Masri, P. García-Pavía, S. Saberi, Neal K. Lakdawala, M. Wheeler, A. Owens, M. Kubanek, W. Wojakowski, M. Jensen, J. Gimeno-Blanes, K. Afshar, J. Myers, Sheila M. Hegde, S. Solomon, A. Sehnert, David X. Zhang, Wanying Li, Mondira Bhattacharya, J. Edelberg, C. Waldman, Steven J. Lester, Andrew Wang, C. Ho, D. Jacoby   +27 more
semanticscholar   +1 more source

Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis

Future Science OA, 2023
Aim: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy. Methods & materials: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies ...
Areeba Memon, Muhammad Omar Larik, Zoha Khan, Maryam Urooj, Areeka Irfan, Beena Kumari, Mehak Faisal, Rida Siddiqui, Moniba Tehrim, Ishaque Hameed   +9 more
doaj   +1 more source

Translating cardiovascular ion channel and Ca2+ signalling mechanisms into therapeutic insights

The Journal of Physiology, EarlyView.
Abstract figure legend This white paper integrates mechanistic discoveries across ion channel biology, Ca2+ signalling and multiscale cardiovascular physiology to highlight new opportunities for accelerating research and guiding next‐generation therapies. Printed with permission from ®Anita Impagliazzo Medical Illustration. [Correction added on 2 March
Silvia Marchianò, Miguel Martín‐Aragón Baudel, Charlotte E. R. Smith, Gonzalo Hernandez Hernandez, Donald M. Bers, Patrick M. Boyle, Dobromir Dobrev, Shanna Hamilton, Osama F. Harraz, Na Li, Thomas A. Longden, William E. Louch, Madeline Nieves‐Cintron, Matthew A. Nystoriak, Walter Lee Murfee, Przemysław B. Radwański, Swapnil K. Sonkusare, Manuel F. Navedo, Eleonora Grandi   +18 more
wiley   +1 more source

Pharmacokinetics and safety of mavacamten in healthy Chinese participants with different CYP2C19 phenotypes

Clinical and Translational Science
Obstructive hypertrophic cardiomyopathy (oHCM) is a subtype of HCM characterized by left ventricular outflow tract obstruction resulting from cardiac muscle hypertrophy and anatomic alterations in the mitral valve and apparatus.
Xiaojie Wu, Nanye Chen, Peiwen Hsu, Jing Sun, Wenting Li, Qi Wang, Merali Samira, Qiong Wei, Jicheng Yu, Guoying Cao, Haijing Yang, Lili Wang, Jingjing Wang, Yi Jin, Wei Liu, Jufang Wu, Jinjie He, Cheng Lyu, Jing Zhang   +18 more
doaj   +1 more source

Genotype‐Dependent Effects of Mechanical Stretch and GATA4‐Targeted Compound 3i‐1262 in Cardiomyopathy Patient–Derived hiPSC‐Cardiomyocytes

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 3, September 2026.
ABSTRACT Genetic hypertrophic and dilated cardiomyopathies (HCM and DCM, respectively) are characterised by structural and functional abnormalities that can lead to heart failure. However, current therapies mainly reduce symptoms. Patient‐derived human induced pluripotent stem cell (hiPSC)–derived cardiomyocytes provide a valuable platform to study ...
Saana Pohjavaara, Sini M. Kinnunen, Heikki Ruskoaho, Katriina Aalto‐Setälä, Mika J. Välimäki, Virpi Talman   +5 more
wiley   +1 more source

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

Open Heart
Background Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman, A. Akram, Bisma Akram, Momina Maham, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Furqan Yaqub   +7 more
semanticscholar   +1 more source